Role of vinpocetine in cerebrovascular diseases
A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and pl...
Gespeichert in:
| Veröffentlicht in: | Pharmacological reports 2011, Vol.63 (3), p.618-628 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 628 |
|---|---|
| container_issue | 3 |
| container_start_page | 618 |
| container_title | Pharmacological reports |
| container_volume | 63 |
| creator | Patyar, Sazal Prakash, Ajay Modi, Manish Medhi, Bikash |
| description | A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Nonclinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases. |
| doi_str_mv | 10.1016/S1734-1140(11)70574-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_885054408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1734114011705746</els_id><sourcerecordid>885054408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-f50d109bb2969b8c54584b54458ebf656d43bd7501f84a3153a899ae01e5d19b3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCaDsgEWoJ7ETZ4VQxUuqhMRjbdnOBLlK42I3lfh73AfdduNZ-Nw7mkPIJdA7oFCMP6DMWQrA6A3AbUl5ydLiiAyzrKpSXgh2TIZ7ZEDOQphRyiDL-SkZZCB4Sct8SMbvrsXENcnKdgtncGk7TGyXGPSovVupYPpW-aS2AVXAcE5OGtUGvNjNEfl6evycvKTTt-fXycM0NQxgmTac1kArrbOqqLQwnHHBNGdxoG4KXtQs13XJKTSCqRx4rkRVKaSAvIZK5yNyve1dePfTY1jKuQ0G21Z16PogheA01lERSb4ljXcheGzkwtu58r8SqFyrkhtVcu0hPnKjShYxd7Xb0Os51vvUv5sIFFsgxK_uG72cud538eqDzffbIEZBKxuDwVjsDNbWo1nK2tkDDX-p1IeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>885054408</pqid></control><display><type>article</type><title>Role of vinpocetine in cerebrovascular diseases</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Alma/SFX Local Collection</source><creator>Patyar, Sazal ; Prakash, Ajay ; Modi, Manish ; Medhi, Bikash</creator><creatorcontrib>Patyar, Sazal ; Prakash, Ajay ; Modi, Manish ; Medhi, Bikash</creatorcontrib><description>A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Nonclinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases.</description><identifier>ISSN: 1734-1140</identifier><identifier>EISSN: 2299-5684</identifier><identifier>DOI: 10.1016/S1734-1140(11)70574-6</identifier><identifier>PMID: 21857073</identifier><language>eng</language><publisher>Cham: Elsevier Urban & Partner Sp. z o.o</publisher><subject>Animals ; Brain Ischemia - drug therapy ; Brain Ischemia - physiopathology ; cerebrovascular ; Cerebrovascular Disorders - drug therapy ; Cerebrovascular Disorders - physiopathology ; Drug Safety and Pharmacovigilance ; Humans ; ischemia ; Memory - drug effects ; neuroprotection ; Neuroprotective Agents - adverse effects ; Neuroprotective Agents - pharmacology ; nootropic ; Nootropic Agents - adverse effects ; Nootropic Agents - pharmacology ; Pharmacotherapy ; Pharmacy ; positron emission tomography ; Review ; Stroke - drug therapy ; Stroke - physiopathology ; Vinca Alkaloids - adverse effects ; Vinca Alkaloids - pharmacology ; vinpocetine</subject><ispartof>Pharmacological reports, 2011, Vol.63 (3), p.618-628</ispartof><rights>2011 Institute of Pharmacology Polish Academy of Sciences</rights><rights>Maj Institute of Pharmacology, Polish Academy of Sciences 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-f50d109bb2969b8c54584b54458ebf656d43bd7501f84a3153a899ae01e5d19b3</citedby><cites>FETCH-LOGICAL-c411t-f50d109bb2969b8c54584b54458ebf656d43bd7501f84a3153a899ae01e5d19b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1016/S1734-1140(11)70574-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1016/S1734-1140(11)70574-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21857073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patyar, Sazal</creatorcontrib><creatorcontrib>Prakash, Ajay</creatorcontrib><creatorcontrib>Modi, Manish</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><title>Role of vinpocetine in cerebrovascular diseases</title><title>Pharmacological reports</title><addtitle>Pharmacol. Rep</addtitle><addtitle>Pharmacol Rep</addtitle><description>A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Nonclinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases.</description><subject>Animals</subject><subject>Brain Ischemia - drug therapy</subject><subject>Brain Ischemia - physiopathology</subject><subject>cerebrovascular</subject><subject>Cerebrovascular Disorders - drug therapy</subject><subject>Cerebrovascular Disorders - physiopathology</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Humans</subject><subject>ischemia</subject><subject>Memory - drug effects</subject><subject>neuroprotection</subject><subject>Neuroprotective Agents - adverse effects</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>nootropic</subject><subject>Nootropic Agents - adverse effects</subject><subject>Nootropic Agents - pharmacology</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>positron emission tomography</subject><subject>Review</subject><subject>Stroke - drug therapy</subject><subject>Stroke - physiopathology</subject><subject>Vinca Alkaloids - adverse effects</subject><subject>Vinca Alkaloids - pharmacology</subject><subject>vinpocetine</subject><issn>1734-1140</issn><issn>2299-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwCaDsgEWoJ7ETZ4VQxUuqhMRjbdnOBLlK42I3lfh73AfdduNZ-Nw7mkPIJdA7oFCMP6DMWQrA6A3AbUl5ydLiiAyzrKpSXgh2TIZ7ZEDOQphRyiDL-SkZZCB4Sct8SMbvrsXENcnKdgtncGk7TGyXGPSovVupYPpW-aS2AVXAcE5OGtUGvNjNEfl6evycvKTTt-fXycM0NQxgmTac1kArrbOqqLQwnHHBNGdxoG4KXtQs13XJKTSCqRx4rkRVKaSAvIZK5yNyve1dePfTY1jKuQ0G21Z16PogheA01lERSb4ljXcheGzkwtu58r8SqFyrkhtVcu0hPnKjShYxd7Xb0Os51vvUv5sIFFsgxK_uG72cud538eqDzffbIEZBKxuDwVjsDNbWo1nK2tkDDX-p1IeA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Patyar, Sazal</creator><creator>Prakash, Ajay</creator><creator>Modi, Manish</creator><creator>Medhi, Bikash</creator><general>Elsevier Urban & Partner Sp. z o.o</general><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Role of vinpocetine in cerebrovascular diseases</title><author>Patyar, Sazal ; Prakash, Ajay ; Modi, Manish ; Medhi, Bikash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-f50d109bb2969b8c54584b54458ebf656d43bd7501f84a3153a899ae01e5d19b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Brain Ischemia - drug therapy</topic><topic>Brain Ischemia - physiopathology</topic><topic>cerebrovascular</topic><topic>Cerebrovascular Disorders - drug therapy</topic><topic>Cerebrovascular Disorders - physiopathology</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Humans</topic><topic>ischemia</topic><topic>Memory - drug effects</topic><topic>neuroprotection</topic><topic>Neuroprotective Agents - adverse effects</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>nootropic</topic><topic>Nootropic Agents - adverse effects</topic><topic>Nootropic Agents - pharmacology</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>positron emission tomography</topic><topic>Review</topic><topic>Stroke - drug therapy</topic><topic>Stroke - physiopathology</topic><topic>Vinca Alkaloids - adverse effects</topic><topic>Vinca Alkaloids - pharmacology</topic><topic>vinpocetine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patyar, Sazal</creatorcontrib><creatorcontrib>Prakash, Ajay</creatorcontrib><creatorcontrib>Modi, Manish</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patyar, Sazal</au><au>Prakash, Ajay</au><au>Modi, Manish</au><au>Medhi, Bikash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of vinpocetine in cerebrovascular diseases</atitle><jtitle>Pharmacological reports</jtitle><stitle>Pharmacol. Rep</stitle><addtitle>Pharmacol Rep</addtitle><date>2011</date><risdate>2011</risdate><volume>63</volume><issue>3</issue><spage>618</spage><epage>628</epage><pages>618-628</pages><issn>1734-1140</issn><eissn>2299-5684</eissn><abstract>A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Nonclinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases.</abstract><cop>Cham</cop><pub>Elsevier Urban & Partner Sp. z o.o</pub><pmid>21857073</pmid><doi>10.1016/S1734-1140(11)70574-6</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1734-1140 |
| ispartof | Pharmacological reports, 2011, Vol.63 (3), p.618-628 |
| issn | 1734-1140 2299-5684 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_885054408 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Alma/SFX Local Collection |
| subjects | Animals Brain Ischemia - drug therapy Brain Ischemia - physiopathology cerebrovascular Cerebrovascular Disorders - drug therapy Cerebrovascular Disorders - physiopathology Drug Safety and Pharmacovigilance Humans ischemia Memory - drug effects neuroprotection Neuroprotective Agents - adverse effects Neuroprotective Agents - pharmacology nootropic Nootropic Agents - adverse effects Nootropic Agents - pharmacology Pharmacotherapy Pharmacy positron emission tomography Review Stroke - drug therapy Stroke - physiopathology Vinca Alkaloids - adverse effects Vinca Alkaloids - pharmacology vinpocetine |
| title | Role of vinpocetine in cerebrovascular diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T12%3A30%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20vinpocetine%20in%20cerebrovascular%20diseases&rft.jtitle=Pharmacological%20reports&rft.au=Patyar,%20Sazal&rft.date=2011&rft.volume=63&rft.issue=3&rft.spage=618&rft.epage=628&rft.pages=618-628&rft.issn=1734-1140&rft.eissn=2299-5684&rft_id=info:doi/10.1016/S1734-1140(11)70574-6&rft_dat=%3Cproquest_cross%3E885054408%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=885054408&rft_id=info:pmid/21857073&rft_els_id=S1734114011705746&rfr_iscdi=true |